Media Mix News - Pharmaceutical Executive

ADVERTISEMENT

Media Mix News

NEJM's New Look

November 1, 2002

The year 2003 will bring more than glad tidings for the New England Journal of Medicine. Jeffrey M. Drazen, MD, editor-in-chief, unveiled the peer-reviewed journal's new design at a recent luncheon hosted for pharma executives, media planners, and agency representatives.

Conference Capsule: Silos to Synergies in Med Ed

November 1, 2002

The 13th annual conference of the National Task Force on Continuing Medical Education Provider/Industry Collaboration, held in Baltimore, Maryland in early September, offered a balanced discussion of the challenges facing CME and helped broker a dialogue among all stakeholders-including representatives of industry, accrediting institutions, academia, and government-with an optimism missing from previous conferences.

PhRMA Gets Its Own PR

November 1, 2002

Seeking to improve its image both inside and outside of the pharma industry, the Pharmaceutical Research and Manufacturers of America (PhRMA) created a strategic communications and public affairs division and tapped market veteran Mark Merritt to head the venture.

Rx for Drug Marketers: Tackling DTC

November 1, 2002

In early October, the Advertising Club of New York sponsored a luncheon titled "Rx for Drug Marketers: Tackling DTC."

Math for the Marketing Mix

November 1, 2002

The newest study released by the Association of Medical Publishers (AMP) suggests that pharma companies could improve their return on investment by taking a more mathematical approach to determining the marketing mix.

Pediatric Rx Spending Escalates

November 1, 2002

Children and teenagers under the age of 19 are the fastest growing segment of prescription medicine consumers in the United States, according to a new study commissioned by the pharmacy benefit manager Medco Health Solutions.

Competition for Viagra

November 1, 2002

Bayer and GlaxoSmithKline are preparing to launch the erectile dysfunction therapy Levitra (vardenafil) next year, in an effort to steal US market share from Pfizer's dominant ED brand Viagra (sildenafil), one of the most successful prescription drug launches in US history.

One Product's Value

October 1, 2002

Like the rest of the financial community, market-weary pharma and biotech investors have become hypersensitive to news reports of the cyclical ups and downs of companies' research and regulatory activities.

Market Pulse: Healthy investments

October 1, 2002

Although the stream of venture capital dollars decreased for most industries from the first to second quarter of 2002, Growthink Research reports that investments in healthcare companies increased.

ADVERTISEMENT

Click here